Gnosis by Lesaffre has relaunched Adonat Premium SAMe (S-Adenosyl-L-Methionine) with a new production line. SAMe is a natural molecule evidenced to support healthy mood and emotional well-being, as it is directly involved in the methylation of neurotransmitters. It is also linked to cognitive function by counteracting alterations in brain structure and function tied to the aging process. SAMe is also linked to liver and joint health benefits, according to Gnosis.
 
Gnosis said that demand for cognitive and mood support ingredients has escalated as a result of an aging population, a rise in neurodegenerative diseases, the COVID-19 pandemic, and a phenomenon referred to as “digital dementia.”
 
“Consumers prioritize their mental well-being,” said Philippe Caillat, Gnosis by Lesaffre’s global marketing director. “That’s what pushed us to continue investing in SAMe to target mood and brain health solutions. Balanced mental health is perceived as equally important as physical health for modern consumers. We’re here to bring to market new solutions with SAMe.”
 
By the end of this year, the company will double its capacity of its GMP manufacturing operations in Sant’Antonino, Switzerland, to better differentiate Adonat Premium SAMe.
 
“On top of more traditional fields of application, there is a new set of areas that the scientific community is exploring,” said Caillat. “Epigenetics, longevity, attention, concentration, and stress and anxiety will be new and strategic segments where SAMe can have a predominant role, overcoming new challenges linked to a global population growing fast and getting older, and its future age-related cognitive decline.”